Copyright 2021 The Korean Society of Neuro-Ophthalmology http://neuro-ophthalmology.co.kr S11
치료 업데이트: 시신경척수염에서 시신경염의 치료
이태경
순천향대학교 부천병원 신경과
Update of Treatment, Not Easy to Cure Neuromyelitis Optica and Optic Neuritis
Tae‑Kyeong Lee, MD
Department of Neurology, Soonchunhyang University, College of Medicine, Bucheon, Korea
ISSN: 2234-0971 대한안신경의학회지: 제11권 Supplement 1
Clin Neuroophthalmol 11(Suppl 1):S11-11, May 2021
Optic neuritis (ON) is a common presenting sign and often a harbinger of central nervous system (CNS) demyelinating disorders such as neuromyelitis optica spectrum disorders(NMOSD), multiple sclerosis, myelin oligodendrocyte glycoprotein(MOG) disease, and glial fibrillary acidic protein (GFAP) disease. ON is more severe and more difficult to management in NMOSD than in classical multiple sclerosis. ON in NMOSD often occurred bilaterally and manifest severe visual loss while most MS patients recover signifi- cant visual acuity following ON. Immunosuppression and plasma exchange are the mainstays of therapy for ON in NMOSD. Man- agement strategies of ON in NMOSD are to minimize vision loss, improve long-term surveillance strategies, and minimize CNS in- jury and disability. Recently, there have been many clinical trials targeting specific steps in NMO pathogenesis including blockers of AQP4-IgG binding to AQP4 and inhibitors of granulocyte function. However, much work remains in understanding the unique susceptibility of the optic nerves in NMOSD and in improving therapies to preserve vision. The major clinical aspects of ON in NMOSD and recent therapeutic options were reviewed.
